Plasmanate as a medium supplement for in vitro fertilization

rct OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-12

This study compared Plasmanate to maternal serum as an in vitro fertilization medium supplement, finding a higher pregnancy rate in a retrospective analysis but not in a prospective trial.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text

This retrospective and prospective study evaluated Plasmanate, a protein preparation containing human serum albumin and mixed globulins, as a supplement to IVF fertilization media compared with autologous preovulatory maternal serum, using 1019 consecutive IVF cycles where Plasmanate was used most often when serum was unavailable or unsuitable (including in some cases such as endometriosis). In retrospective analyses and a matched comparison of 450 patient cycles controlling for medium-lot and laboratory conditions, clinical pregnancy rates differed between Plasmanate and maternal serum, and the direction of the association was not consistent when tested in a prospective randomized trial in patients with tubal infertility attempting IVF for the first time. The authors conclude that Plasmanate may be an appropriate protein substitute where serum cannot be used, while noting that further investigation is necessary. Relevance to endometriosis: the paper states Plasmanate was used in “cases involving… endometriosis” within its clinical usage patterns, though the study’s primary focus is IVF medium protein supplementation rather than endometriosis biology or treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: The purpose of this study was to evaluate the use of Plasmanate, a protein preparation containing human serum albumin and mixed globulins to autologous preovulatory maternal serum, as an in vitro fertilization (IVF) medium supplement. Plasmanate was used most often in cases involving unexplained infertility, sperm antibodies, and endometriosis or when serum was unavailable. RESULTS: In a retrospective analysis of 1019 consecutive IVF cycles, Plasmanate was used as the protein supplement to the fertilization medium in 28.6% and maternal serum was used in 71.4% of the attempts. Attempting to eliminate the effects of different medium lots and laboratory conditions, 450 matched patient cycles were compared using the two protein supplements. Finally, the effects of Plasmanate versus maternal serum were compared in prospective randomized trial on patients diagnosed with tubal infertility who were attempting IVF for the first time. The clinical pregnancy rate was 34% for the Plasmanate group versus 24% for those using maternal serum in the retrospective investigation. However, this trend was reversed in the prospective trial. CONCLUSION: Although further investigation is necessary, it appears that Plasmanate is an appropriate protein substitute in patient cases where serum is absent or unsuitable.
Full text 5,716 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Results

In a retrospective analysis of 1019 consecutive IVF cycles, Plasmanate was used as the protein supplement to the fertilization medium in 28.6% and maternal serum was used in 71.4% of the attempts. Attempting to eliminate the effects of different medium lots and laboratory conditions, 450 matched patient cycles were compared using the two protein supplements. Finally, the effects of Plasmanate versus maternal serum were compared in prospective randomized trial on patients diagnosed with tubal infertility who were attempting IVF for the first time. The clinical pregnancy rate was 34% for the Plasmanate group versus 24% for those using maternal serum in the retrospective investigation. However, this trend was reversed in the prospective trial.

Conclusion

Although further investigation is necessary, it appears that Plasmanate is an appropriate protein substitute in patient cases where serum is absent or unsuitable. Similar content being viewed by others

References

Lopata A: Success and failure in human in vitro fertilization. Nature 1980;288:642 Edwards RG, Fishel SB, Cohen J, Fehilly CB, Purdy JM, Slater JM, Streptoe PC, Webster JM: Factors influencing the success of in vitro fertilization for alleviating human infertility. J Vitro Fert Embryo Transfer 1984;1:3–23 Kemeter P, Feichtinger W: Pregnancy following in vitro fertilization and embryo transfer using pure human serum as culture and transfer medium. Fertil Steril 1984;41:936–937 Holst N, Bertheussen K, Forsdahl F, Berger Hakonsen M, Hansen LJ, Nielsen HI: Optimization and simplification of culture conditions in in vitro fertilization (IVF) and preembryo replacement by serum-free media. J Vitro Fert Embryo Transfer 1990;7:47–53 Jinno M, Iida E, Iizuda R: A detrimental effect of platelets on mouse embryo development. J Vitro Fert Embryo Transfer 1987;4:324–330 Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 1986;46:155–169 Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. Oxford, Clarendon Press, 1986 Hensleigh HC: Optimal concentration of human serum albumin for in vitro murine embryonic development. SSR Meeting 1986;99 Quinn P, Warnes GM, Kerin JF, Kirby C: Culture factors in relation to the success of in vitro fertilization and embryo transfer. Fertil Steril 1984;41:202–209 Trounson A, Conti A: Research in human in vitro fertilisation and embryo transfer. Br Med J 1982;285:244–247 Ackerman SB, Swanson RJ, Stokes GK, Veeck L: Culture of mouse preimplantation embryos as a quality control assay for human in vitro fertilization. Gamete Res 1984;9:145–152 Case Gould M: Endotoxin in vertebrate cell culture: Its measurement and significance. Uses Standard Vertebr Cell Cultures 1984;5:125–136 Hink JH, Jr., Hildalgo J, Seeberg VP: Preparation and properties of a heat-treated human plasma protein fraction. Vox Sang 1957;2:174–186 Cohen J, Malter HE, Talansky BE, Grifo J: Micromanipulation of Human Gametes and Embryos. New York, Raven Press, 1992 Berkeley AS, Bedford JM, Rosenwaks Z: Clinical Aspects of Human in Vitro Fertilization, P Wassarman (ed). Boca Raton, FL, CRC Press, 1991 Rosenwaks Z, Davis OK: In vitro fertilization and related techniques.In Danforth's Obstetrics and Gynecology, 6th ed, JR Scott, PJ DiSaiz, CB Hammond, WN Spellacy (eds). Philadelphia, Lippincott, 1990, pp. 821–843 Sharma V, Riddle A, Mason BA, Pampiglione J, Campbell S: An analysis of factors influencing the establishment of a clinical pregnancy in an ultrasound-based ambulatory in vitro fertilization program. Fertil Steril 1988;48:468–478 Medical Research International, Society for Assisted Reproductive Technology and The American Fertility Society: In vitro fertilization-embryo transfer (IVF-ET) in the United States 1989 results from the IVF-ET Registry. Fertil Steril 1991;55:14–23 Menezo Y, Testart J, Perrone D: Serum is not necessary in human in vitro fertilization, early embryo culture, and transfer. Fertil Steril 1984;42:750–755 Caro CM, Trounson A: Successful fertilization, embryo development, and pregnancy in human in vitro fertilization (IVF) using chemically defined culture medium containing no protein. J Vitro Embryo Transfer 1984;3:215–217 Ashwood-Smith MJ, Hollands P, Edwards RG: The use of Albuminar (TM) as a medium supplement in clinical IVF. Hum Reprod 1989;4:702–705 Staissen C, Van den Abbeel E, Carle M, Khan I, Devroey P, Van den Steirteghem AC: Comparison between human serum and Albuminar-20 (TM) supplement for in-vitro fertilization. Hum Reprod 1990;5:336–341 de Ziegler D, Cedars MI, Hamilton F, Moreno T, Meldrum DR: Factors influencing maintenance of sperm motility during in vitro processing. Fertil Steril 1987;48:816–820 Caro CM, Trounson A: The effect of protein on preimplantation mouse embryo development in vitro. J Vitro Embryo Transfer 1984;1:183–187 Lippes J, Krasner J, Alfonso LA, Dacalos ED, Lacero R: Human oviductal fluid proteins. Fertil Steril 1981;36:623–629 Author information Authors and Affiliations Rights and permissions About this article Cite this article Adler, A., McVicker Reing, A., Bedford, J.M. et al. Plasmanate as a medium supplement for in vitro fertilization. J Assist Reprod Genet 10, 67–71 (1993). https://doi.org/10.1007/BF01204443 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF01204443

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

MeSH descriptors

Blood Proteins Culture Media Fertilization in Vitro Adult Female Fertilization in Vitro Humans Plasma Substitutes Pregnancy Prospective Studies Retrospective Studies Serum Albumin Serum Albumin, Human Serum Globulins Treatment Outcome

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
pubmed
last seen: 2026-05-13T22:11:39.448046+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine